Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05365971 · ClinicalTrials.gov registry record
RISE FOR HEALTH Study
A clinical trial of Lower Urinary Tract Symptoms, sponsored by University of Minnesota.
- Completed
- Registry status
- 3,400
- Enrollment target
- 9
- Study locations
NCT05365971: Completed study of Lower Urinary Tract Symptoms, sponsored by University of Minnesota.
NCT05365971 is a study of Lower Urinary Tract Symptoms that has completed, run by University of Minnesota. The registered enrollment target is 3,400 participants, above the 589-participant average among 21 other Lower Urinary Tract Symptoms trials with a reported enrollment target (477% higher). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05365971, a study of Lower Urinary Tract Symptoms, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 3,400 participants
- Enrollment target
- 9
- Study locations
Study Summary
The RISE FOR HEALTH study (RISE) is an initiative of the Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium, which was formed by the NIDDK in 2015 to develop the science to improve bladder health in women and girls. RISE is designed to identify risk and protective factors for bladder health and lower urinary tract symptoms (LUTS) and to estimate the distributions of bladder health and bladder health knowledge, attitudes, and beliefs in women of all ages across the life course. This will be accomplished by conducting a population-based prospective cohort study. A sample of individuals who live within the study base, i.e., the county containing each PLUS clinical research center and each adjacent county, will be invited to complete two baseline surveys and then two follow-up surveys one year later. A subset of participants will be invited to attend an in-person evaluation to collect additional clinical information and biologic specimens.
Primary Outcome
Multi-item measurement to assess bladder health comprised of subscales and indices ranging from zero to 100
Conditions Studied
Study Locations (9)
Illinois
- Loyola University Chicago - Chicago
- Northwestern University - Chicago
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California, San Diego - San Diego
Connecticut
- Yale University - New Haven
Georgia
- Emory University - Atlanta
Michigan
- University of Michigan - Ann Arbor
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,400 participants |
| Start Date | 2022-05-14 |
| Est. Completion | 2025-06-30 |
What the finished NCT05365971 record still lists
NCT05365971 is an observational study that tracks outcomes without assigning an intervention. Its 3,400 participants enrollment target places it among the larger protocols in the corpus, above the 589-participant average among 21 other Lower Urinary Tract Symptoms trials with a reported enrollment target (477% higher).
The record links to 1 condition, with Lower Urinary Tract Symptoms appearing as the primary indexed condition, and to 0 interventions.
NCT05365971 lists 9 locations in 8 states (Illinois, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT05365971 about?
NCT05365971 is a clinical study titled "RISE FOR HEALTH Study". The RISE FOR HEALTH study (RISE) is an initiative of the Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium, which was formed by the NIDDK in 2015 to develop the science to improve bladder health in women and girls. RISE is designed to identify risk and protective factors for blad...
What is the current status of trial NCT05365971?
This trial is currently completed. The enrollment target is 3,400 participants. The study started on 2022-05-14. Estimated completion is 2025-06-30.
What conditions does trial NCT05365971 study?
This clinical trial studies the following conditions: Lower Urinary Tract Symptoms.
Who is sponsoring clinical trial NCT05365971?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05365971 being conducted?
This trial has 9 study locations across Alabama, California, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lower Urinary Tract Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05365971's enrollment target sits among peer trials
3,400 2nd of 21 the highest of 21 other Lower Urinary Tract Symptoms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lower Urinary Tract Symptoms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
US Imaging for the Assessment of LUTS
RECRUITING
-
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
RECRUITING · Phase 2
-
Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate
RECRUITING · NA
-
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
RECRUITING · NA
-
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
RECRUITING · NA
-
BPH Global Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI